Intestinal inflammation in patients on long term NSAIDs
| No studied | No abnormal | 4 day faecal excretion of 111In white cells (% dose) | |
| Normal controls | 22 | 0 | 0.5 (0.2)% |
| Patient controls | 20 | 3 | 0.6 (0.3)% |
| Indomethacin | 52 | 30 | 4.1 (2.9)%5-150 |
| Piroxicam | 28 | 15 | 3.9 (1.1)%5-150 |
| Naproxen | 58 | 42 | 3.9 (0.8)%5-150 |
| Ibuprofen | 29 | 16 | 3.0 (1.2)%5-150 |
| Flurbiprofen | 16 | 9 | 4.5 (3.2)%5-150 |
| Ketoprofen | 14 | 9 | 3.5 (1.8)%5-150 |
| Diclofenac | 38 | 24 | 4.4 (4.8)%5-150 |
| Aspirin | 7 | 1 | 0.7 (0.3)% |
| Sulindac | 9 | 5 | 2.5 (1.9)%5-150 |
| Etodolac | 11 | 7 | 3.7 (2.1)%5-150 |
| Fenbufen | 11 | 6 | 2.7 (2.3)%5-150 |
| Nabumetone | 13 | 2 | 1.1 (0.4)% |
Values represent mean (SD) faecal excretion of111Indium labelled neutrophils (% dose) following intravenous instillation.
↵5-150 Differs significantly (ANOVA) from normal and patient controls, p<0.05.